Skip to content
Sign in
Artwork for Longevity.Technology UNLOCKED
Health & Fitness

Longevity.Technology UNLOCKED

Longevity.Technology

Longevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living.

🎙 Mondays: In-depth conversations with scientists, founders, investors, operators, and elite performers shaping the longevity ecosystem.
🧠 Fridays: A sharp weekly round-up of the biggest stories, trends, and insights from across the longevity space.

If you’re curious about the future of health, performance, and lifespan, this is where it gets UNLOCKED.

Play
Open in
  • 25 episodes
  • a few times a week
  • Avg 38 min
  • English

Episodes 25

NewestOldestLongest
All5Unplayed5In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • June 19 · 27 min

    The Rise of Preventive Longevity Medicine | Longevity News Roundup — Week 25, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 off-ramps, ovarian aging, combination longevity therapies, AI-driven aging models, Alzheimer’s prevention, and regenerative stem cell advances. Fractyl Health released one-year data from its REVEAL-1 study, showing patients maintained roughly 78% of their GLP-1-related weight loss after receiving the Revita procedure. The results raise the possibility of a long-term off-ramp for Ozempic and similar drugs, though controlled trials are still needed. The Longevity Science Foundation launched a campaign to accelerate ovarian aging research, an area many experts consider critically underfunded despite its relevance to female healthspan and aging biology. Immorta Bio published peer-reviewed preclinical findings showing more than a 70% lifespan increase when senescent cell clearance was combined with regenerative therapies, supporting the idea that multiple aging mechanisms may need to be addressed simultaneously. Gero secured $17 million in new funding and expanded its collaboration with Chugai Pharmaceutical, applying physics-based models and large-scale human datasets to identify aging-related therapeutic targets. Eli Lilly signed a deal potentially worth more than $1 billion with AlzeCure Pharma to develop a preventive Alzheimer's therapy aimed at stopping disease processes years before symptoms emerge. MuseCell Innovations continues advancing stress-resistant stem cell therapies designed to repair damaged tissue while potentially opening new pathways for regenerative longevity medicine. ---------- News & References: A new off-ramp from Ozempic and Wegovy? → https://longevity.technology/news/a-new-off-ramp-from-ozempic-and-wegovy/ Can crowdfunding change ovarian aging research (and opinions)? → https://longevity.technology/news/can-crowdfunding-change-ovarian-aging-research-and-opinions/ Dual stem cell and anti-aging therapy extends mouse lifespan by over 70% → https://longevity.technology/news/dual-stem-cell-and-anti-aging-therapy-extends-mouse-lifespan-by-over-70/ Gero raises $17m to model the mathematics of aging → https://longevity.technology/news/gero-raises-17m-to-model-the-mathematics-of-aging/ Lilly places $1b bet on AlzeCure’s Alzheimer’s project → https://longevity.technology/news/lilly-places-1b-bet-on-alzecures-alzheimers-project/ Harnessing Muse cells in longevity medicine → https://longevity.technology/news/harnessing-muse-cells-in-longevity-medicine/

  • June 15 · 1 hr

    The Drugs That Could Slow Aging Are Already Here | Dr. Nir Barzilai

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: FlexBeam FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities. Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off. Link: rechargehealthas.sjv.io/jRQyQ5 ---------- Guests: Nir Barzilai Director of the Institute for Aging Research at the Albert Einstein College of Medicine LinkedIn: www.linkedin.com/in/nir-barzilai-7a86a7212/ Link to Nir's works: einsteinmed.edu/faculty/484/nir-barzilai, www.sciencedirect.com/author/7005711408/nir-barzilai ---------- What if aging itself is the biggest medical opportunity of the 21st century? Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once. Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics. Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity. The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model. In this episode, you’ll learn: Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular disease How centenarians compress morbidity and remain healthy into extreme old age Why GLP-1 therapies reduced hospitalization and death by roughly 60% in one study Why Barzilai tracks proteomics and believes biomarkers will transform longevity medicine Which longevity interventions he personally uses, including metformin and Rejuvant If you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

  • June 12 · 30 min

    Can Wearables Become Clinical Tools? | Longevity News Roundup — Week 24, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: https://partners.fatty15.com/UNLOCKED ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine clinical AI, cortisol wearables, blood pressure monitoring, animal longevity biotech, stem cell therapies and next-generation obesity treatments. Longevitix launched a clinical intelligence platform designed for longevity, preventive and functional medicine clinics. The system combines laboratory results, wearable data, clinical notes and patient histories into physician-ready summaries, prioritized insights and personalized intervention plans. Rejuvenate Bio secured $6 million in new financing alongside a strategic collaboration with Merck Animal Health. The partnership aims to advance gene therapies for chronic and age-related conditions in pets, highlighting growing interest in animal longevity as a pathway for translational research. Adaptyx Biosciences presented data on a wearable cortisol sensor capable of continuously tracking free cortisol over multiple days. The device successfully captured daily cortisol rhythms and showed strong agreement with paired blood measurements. Celularity partnered with Fountain Life to offer placental-derived cell therapies at Fountain Life’s Florida facility. The collaboration leverages Florida’s evolving framework for early-stage stem cell treatments and could provide valuable real-world clinical data. South Korea became the first country to include Skylabs’ Cart BP Pro in its national hypertension treatment guidelines. The ring-shaped device continuously monitors blood pressure without the need for a traditional arm cuff, helping detect risks that often go unnoticed during routine clinic visits. MitoRx presented preclinical data for MTRX31, a mitochondrial-targeted obesity therapy designed to improve metabolic health through a mechanism distinct from GLP-1 drugs. The approach could serve as either a standalone treatment or a complementary therapy, making it a potentially attractive target for future pharmaceutical partnerships. ---------- News & References: Longevitix launches AI platform to tackle longevity data overload → https://longevity.technology/news/longevitix-launches-ai-platform-to-tackle-longevity-data-overload/ Rejuvenate Bio secures funding and Merck partnership → https://longevity.technology/news/rejuvenate-bio-secures-funding-and-merck-partnership/ Adaptyx debuts first continuous cortisol tracking wearable → https://longevity.technology/news/adaptyx-debuts-first-continuous-cortisol-tracking-wearable/ Celularity, Fountain Life to offer experimental cell therapy in Florida → https://longevity.technology/news/celularity-fountain-life-to-offer-experimental-cell-therapy-in-florida/ Goodbye, arm cuffs? South Korea bets on ring-type BP monitor → https://longevity.technology/news/goodbye-arm-cuffs-south-korea-bets-on-ring-type-bp-monitor/ MitoRX’s new obesity drug targets metabolism, not appetite → https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/

  • June 8 · 47 min

    Could Banking Your Cells Today Add Healthy Years Tomorrow?

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Acorn Biolabs Acorn Biolabs is a science-driven regenerative medicine company that preserves your own hair follicle stem cells for future personalized treatments. Through a simple, non-invasive collection process, Acorn helps you bank your healthiest cells today, supporting regenerative skincare and hair therapies now while preparing for the future of longevity and cellular medicine. Click the link below to learn more about Acorn's innovative approach to stem cell preservation. Link: www.acorn.me ---------- Guests: Drew Taylor CEO and co-founder of Acorn Biolabs LinkedIn: https://www.linkedin.com/in/drew-taylor-65b6ab10/ Website: www.acorn.me ---------- What if the smartest longevity investment isn’t another supplement or infusion, but preserving your younger cells before aging changes them? Phil Newman and Dr. Nina Patrick sit down with Drew Taylor, CEO and co-founder of Acorn Biolabs and biomedical engineer, to explore how regenerative medicine is shifting from reactive repair toward biological preservation and future optionality. Together they explain why hair follicle stem cells may offer one of the most accessible entry points into autologous regenerative medicine. From collecting stem cells with simple hair plucking instead of invasive bone marrow extraction to cryopreserving younger biology for decades, Drew breaks down how Acorn’s platform aims to freeze cellular aging in time. The conversation also explores how these cells produce secretomes rich in growth factors, cytokines, collagen, extracellular vesicles, and exosomes that can later be used in skin rejuvenation, hair restoration, and orthopedic applications. The discussion also dives into the darker side of the industry, including stem cell tourism, regulatory gaps, misinformation, and the risks patients face when traveling abroad for unverified treatments. Drew argues that ethical regenerative medicine must prioritize transparency, patient safety, and clinically validated protocols over hype. They also explore the future of the field, including NK cells engineered from preserved hair follicle cells, cartilage regeneration research, AI-powered omics analysis, fertility applications, Parkinson’s research, and the possibility of one day growing replacement tissues and organs from your own preserved biology. In this episode, you’ll learn: Why Acorn can generate up to 108 treatment vials from one collection How secretomes deliver growth factors, cytokines, collagen, and exosomes Why stem cell numbers decline faster than stem cell performance with age How NK cells derived from hair follicles suppressed cancer cell growth in lab studies Why Drew believes “cells will become the next currency in healthcare” If you want to understand how regenerative medicine could shift from aesthetics to personalized disease prevention, this episode connects cutting-edge cell science with practical longevity strategies. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

  • June 5 · 22 min

    Are Brain Interfaces Finally Ready For Daily Life? | Longevity News Roundup — Week 23, 2026

    Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: ⁠⁠https://qrco.de/bgXpKn ---------- Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing. Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit. Link: partners.fatty15.com/UNLOCKED ---------- In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine wearable health innovation, brain-computer interfaces, physician-led longevity care, Alzheimer’s research, and the evolution of the longevity industry. ŌURA launched Ring 5, a redesigned device that is 40% smaller while maintaining week-long battery life. New features include blood pressure signals, breathing monitoring, GLP-1 insights, and integrated health data designed to make wearables a central health management platform. Ability Neurotech received approval in the Netherlands to begin long-term studies of its battery-free optical brain implant in ALS patients. The system is designed for everyday home use, highlighting the industry's shift from laboratory demonstrations toward real-world functionality. Elysium Health launched The Elysium Longevity Institute (TELI), combining physician oversight, advanced testing, supplements, prescriptions, and peptides. The move reflects a broader trend of established longevity brands expanding into comprehensive clinical care. A study of 69 women aged 65 and older linked poor sleep, increased Alzheimer’s genetic risk, greater tau accumulation, and weaker visual memory. Researchers suggest sleep and visual memory changes may offer valuable signals of early disease processes. From 95 startups across 32 countries entering the Longevity Show pitch competition to growing investment in diagnostics, prevention platforms, AI, and care delivery, the sector is increasingly focused on translating science into scalable healthspan solutions. The broader transition from sick care to prevention-led systems, where aging biology becomes a core risk factor and healthspan metrics replace disease counting. Insurance, pensions, and healthcare payment models need to adapt as longevity becomes embedded in economic infrastructure, not just products. ---------- News & References: What poor sleep may be telling women about Alzheimer’s? → https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/ Five finalists advance in longevity pitch contest → https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/ ŌURA’s smallest smart ring launched with expanded health monitoring → https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/ Optical brain implant moves into real-world use → https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/ Elysium expands into physician-led longevity care → https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/ Public health faces longevity imperative → https://longevity.technology/news/public-health-faces-longevity-imperative/

Showing 21–25 of 25 episodes